Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Summary from Lane Simonian today on SA:

"For the time being at least, this leaves Anavex's blarcamesine as the best current hope for the near stabilization of Alzheimer's disease over the long-term. Results from Anavex's 48 weeks phase 2b/3 trial may be known late in the Fall.

It is possible that the company will be able to present the results at the CTAD conference in late November and early December.

The pattern of early improvement in some patients that carried all the way through to 109 weeks should be replicated in a much larger trial at 48 weeks. From there even without U.S. trial centers, the FDA should grant accelerated approval, allowing for the sale of the drug, but with continued testing, with U.S. sites, over longer periods of time.

Nothing is for certain, but all of this should give long-time investors in the company considerable optimism and perhaps draw a few new investors before the release of trial results."

Thanks catdaddy, for posting the snippet. I think he is in the sphere of a potential possibilities. Unfortunately so far we have not seen the influx of new investors running the vol and sp up, as shares are bought in advance of news. The current below average volume and suppressed sp is delaying the move up that is expected in anticipation of good AD TLR news, and plus other news releases due before the end of the year.